Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Arizona Tribune - Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.

Text size:

Conference Call Details

Date and Time: Tuesday, February 3, 2026, at 4:30 p.m. Eastern time.

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 567381.

Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53322, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.

Replay: A teleconference replay of the call will be available until February 17, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53322.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.

View the original press release on ACCESS Newswire

R.Chavez--AT

CMSC	0.16%	21.31	$
RBGPF	1.13%	70.69	$
CMSD	0.09%	21.18	$
JRI	-0.32%	12.4	$
VOD	-0.38%	15.88	$
RIO	0.08%	104.78	$
BTI	-2.06%	56.28	$
BCE	-0.38%	23.4	$
AZN	-1.06%	164.52	$
GSK	-2.31%	50.27	$
BCC	-1.49%	78.77	$
RELX	2.64%	36.3	$
BP	-0.38%	42.34	$
NGG	-1.38%	79.43	$
RYCEF	-1.93%	20.75	$

Arizona Tribune - Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Featured

Air traffic controllers left early before deadly NY crash: report

Clashes in Spain's Ceuta month after mass migrant influx

Guns, drugs and car chases: GTA 6 preview lands on Netflix after leaks

Michael Strahan Welcomes Fifth Child with Girlfriend Kayla Quick